Skip to main content
Lupin Ltd logo

Lupin Ltd — Investor Relations & Filings

Ticker · LUPIN ISIN · INE326A01037 LEI · 335800HHXTESDEE2FC65 BSE.NS Manufacturing
Open in API
Filings indexed 3,178 across all filing types
Latest filing 2023-11-23 Regulatory Filings
Country IN India
Listing BSE.NS LUPIN

About Lupin Ltd

https://www.lupin.com/

Lupin Ltd is a global pharmaceutical organization specializing in the development, manufacturing, and marketing of a comprehensive range of generic and branded formulations, biotechnology products, and active pharmaceutical ingredients. The company holds a significant market position in therapeutic segments such as cardiovascular, diabetology, asthma, pediatrics, gastrointestinal, anti-infectives, and non-steroidal anti-inflammatory drugs. It is notably recognized for its leadership in the anti-tuberculosis medication sector. With a strong emphasis on research and development, Lupin focuses on complex generics, specialty medicines, and biosimilars. The company operates advanced manufacturing facilities and maintains a substantial commercial presence across major global markets, including North America, Europe, and the Asia-Pacific region, delivering affordable and high-quality healthcare solutions.

Recent filings

Filing Released Lang Actions
Press Release
Regulatory Filings Classification · 95% confidence The document is a press release announcing the receipt of U.S. FDA approval for a pharmaceutical product. It is addressed to stock exchanges as a disclosure pursuant to a listing regulation, indicating it is a regulatory announcement. The content focuses on the approval news and product details, not on financial results, management changes, or detailed reports. The document length is 4392 characters, which is relatively short and consistent with a press release or regulatory announcement rather than a full report. There is no financial data, no detailed analysis, or comprehensive reporting. Therefore, this document fits best as a Regulatory Filing (RNS) since it is a general regulatory announcement and does not fit other specific categories like earnings release or capital update.
2023-11-23 English
Lupin Receives Approval from U.S. FDA for Bromfenac Ophthalmic Solution, 0.07%.
Regulatory Filings Classification · 95% confidence The document is a press release announcing the receipt of U.S. FDA approval for a pharmaceutical product by Lupin Limited. It is addressed to stock exchanges as a disclosure pursuant to a listing regulation, indicating it is a regulatory announcement. The document does not contain financial statements, detailed financial analysis, or management discussion. It is relatively short (4390 characters) and serves as an announcement of a significant corporate event (FDA approval) rather than a financial report or detailed investor presentation. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2023-11-23 English
Loss of Share Certificates
Regulatory Filings Classification · 95% confidence The document is a compliance certificate under Regulation 39(3) of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015. It details the loss of share certificates and is addressed to stock exchanges. The content is a regulatory compliance communication rather than a financial report, management update, or shareholder meeting material. It does not contain financial statements, earnings data, or management discussion. The document length is short (3070 characters) and it serves as a formal regulatory filing to stock exchanges. Therefore, it fits best under Regulatory Filings (RNS) as a compliance certificate under SEBI regulations.
2023-11-23 English
Intimation regarding loss of share certificate by the shareholders.
Regulatory Filings Classification · 100% confidence The document is a compliance certificate under Regulation 39(3) of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015. It details the loss of share certificates and is addressed to stock exchanges (BSE and NSE). The content is a regulatory compliance communication related to share certificate stop transfer requests. The document is short (3070 characters) and does not contain financial data, management discussion, or report content. It is not an annual report, earnings release, or any financial report. It is a regulatory filing related to compliance with listing obligations. Therefore, the appropriate classification is Regulatory Filings (RNS).
2023-11-23 English
Lupin Launches World''s First Fixed-dose Triple Combination Drug, Vilfuro-G for COPD Management in India.
Regulatory Filings Classification · 95% confidence The document is a press release announcing the launch of a new pharmaceutical product by Lupin Limited. It is addressed to stock exchanges as a disclosure pursuant to Regulation 30 of SEBI Listing Regulations, which pertains to material events or information. The content focuses on product launch information and company background, without any financial statements, detailed financial analysis, or regulatory filings. The document length is about 5160 characters, which is relatively short and primarily an announcement rather than a detailed report. It does not contain financial results, management discussion, or audit information. Therefore, it fits best under the category of a Regulatory Filing (RNS) as a general regulatory announcement and disclosure of material information under listing obligations, rather than a financial report or other specific filing type.
2023-11-23 English
Press Release
Regulatory Filings Classification · 95% confidence The document is a press release announcing the launch of a new pharmaceutical product by Lupin Limited. It is addressed to stock exchanges as a disclosure pursuant to Regulation 30 of SEBI Listing Obligations and Disclosure Requirements, which pertains to material events or information. The content focuses on product launch information and does not contain financial statements, management discussion, or detailed financial data. The document length is about 5,157 characters, which is relatively short and typical for a press release. There is no indication that this is a financial report, earnings release, or regulatory filing beyond the disclosure of a material event. Therefore, this document fits best under the category of Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory announcements and disclosures that do not fit other specific categories.
2023-11-23 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.